文献速递脊柱关节炎

比美吉珠单抗治疗未使用过生物制剂DMARD的活动性银屑病关节炎:III期随机安慰剂对照活性参照BE OPTIMAL研究52周疗效与安全性结果

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
PubMed 文献 · Ann Rheum Dis · 2023-09-11

BE OPTIMAL研究纳入未使用过生物制剂DMARD的活动性银屑病关节炎患者,随机接受比美吉珠单抗160mg每4周、安慰剂(第16周切换至比美吉珠单抗)或阿达木单抗40mg每2周。至第52周,比美吉珠单抗组ACR20/50/70、PASI75/90/100和MDA应答持续,第16周切换者疗效与初始随机比美吉珠单抗者相似;安全性良好,无新安全信号。

要点

  • 比美吉珠单抗在未使用过生物制剂DMARD的银屑病关节炎患者中至第52周疗效持续。
  • 第16周从安慰剂切换至比美吉珠单抗的患者至第52周疗效与初始随机比美吉珠单抗者相似。
  • 至第52周,比美吉珠单抗组555/702(79.1%)发生至少1例治疗中出现的不良事件,阿达木单抗组113/140(80.7%)。

核心结论

  • 比美吉珠单抗在未使用过生物制剂DMARD的银屑病关节炎患者中的疗效从第16周持续至第52周。
  • 比美吉珠单抗耐受性良好,未观察到新的安全信号。

研究设计与样本

  • BE OPTIMAL为III期随机、安慰剂对照、活性参照研究,包含16周双盲安慰剂对照期和随后36周治疗盲期。
  • 患者按3:2:1随机接受皮下比美吉珠单抗160mg每4周、安慰剂(第16周切换至比美吉珠单抗)或参照臂阿达木单抗40mg每2周。
  • 疗效结局包括ACR20/50/70、基线银屑病累及≥3%体表面积患者的PASI75/90/100和MDA,采用无应答者填补。

主要发现

  • 至第52周,比美吉珠单抗组ACR20/50/70、PASI75/90/100和MDA应答持续,与第16周观察到的结果一致。
  • 第16周切换至比美吉珠单抗的患者疗效改善,至第52周结果与初始随机比美吉珠单抗者相似。
  • 至第52周,比美吉珠单抗治疗期间555/702(79.1%)患者发生至少1例治疗中出现的不良事件;阿达木单抗组113/140(80.7%)。
  • 比美吉珠单抗组46例(6.6%)患者发生严重治疗中出现的不良事件。
  • 比美吉珠单抗治疗期间发生54例(7.7%)念珠菌感染,阿达木单抗期间1例(0.7%);所有病例均为局部性且非严重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with active psoriatic arthritis (PsA). Here, we report long-term efficacy and safety to Week 52. METHODS: BE OPTIMAL comprised a 16-week, double-blind, PBO-controlled period, then 36 weeks treatment-blind. Patients were randomised 3:2:1 to subcutaneous BKZ 160 mg every 4 weeks, PBO with switch to BKZ at Week 16, or reference arm (adalimumab (ADA) 40 mg every 2 weeks). Efficacy outcomes included the American College of Rheumatology (ACR) response criteria 20/50/70, Psoriasis Area and Severity Index (PASI) 75/90/100 in patients with baseline psoriasis affecting ≥3% body surface area and minimal disease activity (MDA); non-responder imputation. RESULTS: ACR20/50/70, PASI75/90/100 and MDA responses were sustained with BKZ to Week 52, consistent with results observed at Week 16. Patients who switched to BKZ at Week 16 demonstrated improvements in efficacy with similar results to BKZ-randomised patients by Week 52.To Week 52, 555/702 (79.1%) patients had ≥1 treatment-emergent adverse event (TEAE) during BKZ treatment; 113/140 (80.7%) on ADA. On BKZ, 46 (6.6%) patients had serious TEAEs. 54 (7.7%) Candida infections occurred during BKZ treatment and 1 (0.7%) during ADA; all cases were localised and non-serious. One death occurred in a BKZ-treated patient, unrelated to treatment. CONCLUSIONS: The efficacy of BKZ in bDMARD-naïve patients with PsA was sustained from Week 16 to Week 52. BKZ was well tolerated with no new safety signals observed. TRIAL REGISTRATION NUMBER: NCT03895203.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023. PMID: 37696588. doi:10.1136/ard-2023-224431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。